- Home
- MCRB vs ELUT Comparison
MCRB vs ELUT Comparison
Compare MCRB & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRB | ELUT |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 42.5M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MCRB | ELUT |
|---|---|---|
| Price | $4.68 | $0.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $14.00 | $6.00 |
| AVG Volume (30 Days) | ★ 53.3K | 48.1K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | N/A | ★ N/A |
| Revenue | $789,000.00 | ★ $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.83 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.32 | $0.50 |
| 52 Week High | $29.98 | $2.50 |
Technical Indicators
Market Signals| Indicator | MCRB | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 36.18 | 50.70 |
| Support Level | N/A | $0.87 |
| Resistance Level | $5.65 | $1.06 |
| Average True Range (ATR) | 0.34 | 0.08 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 10.86 | 61.83 |
Price Performance
Historical ComparisonAbout MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
About ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.